Bedrijfsoverzicht
Genenta Science S.p.A. is a clinical-stage biotechnology entity focused on the development of hematopoietic stem cell gene therapies specifically designed to treat solid tumors within the Italian market. The company operates within the broader healthcare sector, where its specific industry classification as biotechnology signifies a high-risk, high-reward environment characterized by significant research and development expenditures before product commercialization. At a macro level, the firm maintains a market capitalization of $15.68 million and employs a workforce of 9 individuals, reflecting a very small-scale operation typical of early-stage therapeutic development firms. These valuation metrics and revenue figures indicate that Genenta Science is a micro-cap entity with limited financial resources and operational footprint, positioning it as a speculative investment where value is derived entirely from the potential future success of its pipeline rather than current operational cash flows.
Financiële gezondheid
The company reports net income of $-6,529,827 and EBITDA of $-6,575,658 over the trailing twelve months, while annual revenue data is not available in the current reporting period. The substantial negative net income relative to the available EBITDA highlights a cost structure dominated by non-operating expenses or one-time charges that depress bottom-line profitability despite operational cash generation efforts. Free cash flow stands at $-3,095,756, indicating that the company is consuming cash reserves to fund its clinical trials and development activities, which severely limits its immediate financial flexibility and ability to operate without external capital injections. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that reflects the company's current stage where costs have outpaced any realized revenue, rendering traditional margin analysis inapplicable to assessing operational efficiency. On the liability side, the company holds $28.15 million in cash against $7.60 million in debt, resulting in a debt-to-equity ratio of 34.81, which suggests a highly leveraged balance sheet relative to equity though the absolute debt burden is manageable given the cash position. The current ratio is reported at 14.15, an exceptionally high figure that indicates robust short-term liquidity and an overwhelming capacity to cover current liabilities with current assets. Finally, the return on equity is -38.0% and the return on assets is -17.7%, metrics that reveal management is currently destroying shareholder value through heavy investment outflows rather than generating returns on the deployed capital base.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is listed as N/A due to the lack of positive earnings, while the forward P/E is -1.03, a negative figure that implies the market is pricing in expected future losses rather than current profitability or growth. The price-to-book ratio is 0.62, suggesting that the market values the company at a significant discount to its net asset book value, which often occurs when investors do not believe the intangible assets or pipeline potential will fully materialize into enterprise value. Price-to-sales and EV/EBITDA metrics are also N/A or negative (0.72 for EV/EBITDA), indicating that traditional valuation multiples are distorted by the lack of revenue and negative earnings, forcing reliance on asset-backed or cash-flow-based alternative metrics for analysis. The stock's 52-week trading range spans from a low of $0.59 to a high of $10.00, providing a wide volatility band within which the current price fluctuates based on clinical trial updates and broader biotech sector sentiment. With a beta of 0.71, the stock exhibits lower price volatility relative to the broader market, moving less aggressively than the general index despite the inherent risks associated with its clinical-stage development model.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of earnings growth rates against revenue expansion since consistent historical revenue data is unavailable in the current dataset. Because the company has not generated positive earnings or paid dividends, there is no dividend yield or payout ratio to analyze, meaning the firm does not return capital to shareholders through distributions but instead retains all resources for reinvestment. Consequently, the company reinvests its remaining cash and potential future earnings into research and development rather than paying dividends, a strategy common for clinical-stage biotechs but one that offers no current income profile. The overall growth and income profile is therefore defined entirely by the speculative potential of the Temferon lead product candidate in Phase 1/2a trials, with no historical growth trajectory or dividend income available to investors for reference.